Rafat Abonour

RT @nabiladra: Great session with colleagues @AdityaBagrodia and @RichMatulewicz discussing multidisciplinary care and complex cases in tes…

⁦@ASCOPres⁩ ⁦@ASCO⁩ , ⁦@IUCancerCenter⁩ is well represented at the scientific committee. Great work will be presented. Thank you Dr Zon for your leadership and vision https://t.co/cE53n2REzU

RT @JenSchwartzIUSM: Zach Meyer presenting 2 posters at #Tandem2025. #IUStemCellTransplant @IUHemOnc @IUSMDeptMed @IUCancerCenter @IUMedSch…

#MSMM #CART #bispecific. Can anyone explain the rationale for using multiple doses in a single week to manage CRS? Half life of antibodies is 2 weeks!

#MSMm #myeloma. I wish Bart Barolgie is still practicing myeloma. He is a genius and great at thinking outside the box. He would cure myeloma today.

On being a #physician I do not think AI, guidelines and protocols can replace an experienced and curious physician.

based on 20 ml of blood and 2.9 cells/ml circulating tumor cells, the natural path doctor told the patient that D-RVD would not work for the cancer. Where is the data #onconomics plus. # myeloma patients beware. https://t.co/14BkIZhWuj

RT @AaronGoodman33: So much of medicine is just waiting, doing nothing, and letting the body (or whatever symptoms/incidental lab/imaging f…

#medicine #radiology #patients. Can we all agree that accessing your radiology results online the same day is more anxiety provoking to the patients. There is no physician around that can address these results right away.

The art of sitting down and listening to the patients and the curiosity to explore are lost in the jungle of ERM and quality metrics among other things we have to do that do nothing to improve the outcomes of our patients.

Aaron Goodman - “Papa Heme” @AaronGoodman33

These days the inpatient service is disheartening. It is sad to see the over medicalization, over treatment, and over testing of our patients. The only thing we don’t over do is actually sitting down and having honest conversations with patients and their family members.

RT @Myeloma_Society: In this episode of IMSound, gain insight into the first results from the eagerly awaited MIDAS study from Aurore Perro…

#IMS24 @IUCancerCenter Our own @suvannasankha presenting on an important bispecific BCMA targeted therapy great success. #regeneron https://t.co/Qjvf3aKEyW

RT @IUCancerCenter: In 1974, the survival rate for testicular cancer was just 5%. Today, thanks to the groundbreaking work of Lawrence Einh…

RT @AaronGoodman33: Doing clinical trial research is painful. Sorry that is my opinion. It is important but painful. There are way too many…

RT @rabonour1: With my boss Kelvin Lee. Let’s make myeloma history. @IUCancerCenter https://t.co/OQkEmYfDQr

With my boss Kelvin Lee. Let’s make myeloma history. @IUCancerCenter https://t.co/OQkEmYfDQr